Inspire Medical Systems, Inc.
NYSE:INSPMedical - Devices
+$0.51 today
- Market cap
- $1.68B
- Beta
- 0.73
- P/E (TTM)
- 9.1
- EPS (TTM)
- $4.57
Volume 0.51M
Average 1.13M
INSP Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Inspire Medical Systems, Inc.NYSE: INSP
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q2 FY2026 depreciation & amortization of $4.6M rose 34.7% year over year, behind the +59.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 10.0% from the prior quarter. Over 3 fiscal years it compounded at +95.8% a year.
Context
- Depreciation & amortization amounted to 1.5% of revenue in FY2025, up 0.7 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +34.7% toward the trailing-twelve-month pace of +59.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 13.96M USD
- Year-over-year change
- +113.1%
- 4-year CAGR
- +84.0%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.96M | +113.1% |
| FY2024 | 2024-12-31 | 6.55M | +130.1% |
| FY2023 | 2023-12-31 | 2.85M | +53.2% |
| FY2022 | 2022-12-31 | 1.86M | +52.5% |
| FY2021 | 2021-12-31 | 1.22M | — |
Depreciation & Amortization vs competitors
How INSP compares with its peers on the latest reported figures
- INSP's LTM Jun 2026 depreciation & amortization of $17.21M is the 5th largest of the 9 companies compared; the peer median is $20.03M.
- Its year-over-year change of +59.5% is the 2nd highest of 9, against a peer median of +12.8%.
- Depreciation & amortization amounts to 1.9% of revenue for INSP, versus a peer median of 4.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $735.2M | +90.4% | +1.5% | 24.9% | |
ARDTArdent Health Partners, LLC | LTM Mar 2026 | $162.49M | +10.4% | +4.1% | 2.5% |
| LTM Jul 2026 | $138.1M | +15.3% | +12.4% | 7.5% | |
| LTM Mar 2026 | $23.35M | -1.6% | +0.0% | 5.1% | |
| LTM Jun 2026 | $17.21M | +59.5% | +95.8% | 1.9% | |
| LTM Jun 2026 | $16.71M | +15.1% | +5.3% | 1.1% | |
| LTM Mar 2026 | $10.49M | +6.6% | +3.4% | 4.1% | |
| LTM Jun 2026 | $10M | +0.0% | +18.6% | 8.5% | |
| LTM Mar 2026 | $6.65M | +20.4% | +31.0% | 2.1% | |
| Peer median (excluding INSP) | $20.03M | +12.8% | +4.7% | 4.6% | |
Competitors are the stored peer set for INSP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (42.04M) | (44.88M) | (21.15M) | 53.51M | 145.42M |
| Depreciation & Amortization | 1.22M | 1.86M | 2.85M | 6.55M | 13.96M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | (88.75M) |
| Stock-Based Compensation | 26.18M | 51.97M | 82.47M | 116.01M | 130.26M |
| Change in Working Capital | (6.86M) | 1.81M | (40.78M) | (37.71M) | (87.38M) |
| Accounts Receivables | (9.24M) | (27.02M) | (30.22M) | (2.6M) | (26.23M) |
| Inventory | (8.75M) | 5.35M | (22M) | (46.23M) | (65.18M) |
| Accounts Payables | 4.78M | 14.36M | 9.3M | 604K | (3.75M) |
| Other Working Capital | 6.36M | 9.13M | 2.14M | 10.52M | 7.77M |
| Other Non-Cash Items | 1.38M | 812K | 1.27M | (7.51M) | 3.47M |
| Operating Cash Flow | (20.12M) | 11.57M | 24.65M | 130.25M | 116.98M |
| Capital Expenditures | (4.67M) | (9.1M) | (23.63M) | (39.12M) | (38.5M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (9.99M) | 0 | (281.44M) | (418.6M) | (250.44M) |
| Sales of Investments | 43.8M | 0 | 10.25M | 344.61M | 310.38M |
| Other Investing Activities | 0 | (10.5M) | 0 | 0 | 0 |
| Investing Cash Flow | 29.14M | (19.6M) | (294.82M) | (113.12M) | 21.45M |
| Debt Repayment | 0 | (24.5M) | 0 | 0 | 0 |
| Common Stock Issued | 14.95M | 259.62M | 31.11M | 27.77M | 14.61M |
| Common Stock Repurchased | 0 | 0 | 0 | (75M) | (175.02M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (43K) | (17.16M) | (5.17M) | (23.04M) |
| Financing Cash Flow | 14.95M | 235.08M | 13.95M | (52.39M) | (183.45M) |
| Effect of Forex Changes | (19K) | 75K | 164K | (118K) | (310K) |
| Net Change in Cash | 23.95M | 227.13M | (256.06M) | (35.39M) | (45.34M) |
| Free Cash Flow | (24.79M) | 2.47M | 1.02M | 91.12M | 78.48M |
Inspire Medical Systems, Inc.
NYSE:INSP
Intrinsic Alpha fair value
Locked
Current Price
$58.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.